

Natural History Of Implantable Cardioverter-Defibrillator Implanted At Or After The Age Of 70 Years In A Veteran Population A Single Center Study

Tarek Ajam,^{1,2} Vikas Kalra,^{1,2} Changyu Shen³ Xiaochen Li,³ Sandeep Gautam,⁴ Thomas Kambur,^{1,2} Mamta Barmada,⁵ Kyle W. Yancey,⁶ Samer Ajam,^{1,2} Jason Garlie,^{1,2} John M. Miller,^{1,2} Rahul Jain^{1,2}

¹Division of Cardiology, Department of Medicine, Richard L Roudebush Veterans Affairs Medical Center, Indianapolis, IN; ²Division of Cardiology, Indiana University School of Medicine, Indianapolis, IN; ³Department of Biostatistics, School of Medicine and Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN; ⁴Division of Cardiovascular Medicine, University of Missouri, Columbia, MO; ⁵Indiana University School of Allied Health Sciences, Indianapolis, IN; ⁶Division of Cardiovascular and Thoracic Surgery, Indiana University School of Medicine, Indianapolis, IN

Abstract

The median age of patients in major Implantable Cardioverter-defibrillator (ICD) trials (MUSTT, MADIT-I, MADIT-II, and SCD-HeFT) was 63-67 years; with only 11% ≥ 70 years. There is little follow-up data on patients over 70 years of age who received an ICD for primary/secondary prevention of sudden cardiac death, particularly for veterans. The aim of this study was to study the natural history of ICD implantation for veterans over 70 years of age. We retrospectively reviewed single center ICD data in 216 patients with a mean age at implantation 76 ± 4 years. The ICD indication was primary prevention in 161 patients and secondary prevention in 55 patients. The ICD indication was unavailable in 4 patients. Mean duration of follow up was 1686 ± 1244 days during which 114 (52%) patients died. Of these, 31% died without receiving any appropriate ICD therapy. Overall, 60/216 (28%) received appropriate therapy and 28/216 (13%) received inappropriate therapy. Patients who had ICD implantation for secondary prophylaxis had statistically more ($p = 0.02$) appropriate therapies compared to patients who had ICD implantation for primary prevention. Indication for implantation and hypertension predicted appropriate therapy, while age at the time of implantation and presence of atrial fibrillation predicted inappropriate therapies. Overall, 7.7% had device related complications. Although 28% septuagenarians in this study received appropriate ICD therapy, they had high rates of mortality, inappropriate therapy, and device complications. ICD implantation in the elderly merits individualized consideration, with higher benefit for secondary prevention.

Introduction:

Implantable cardioverter-defibrillator (ICD) is associated with reduction in arrhythmic death when implanted for either primary or secondary prevention of sudden cardiac death. [1], [2], [3], [4], [5]. More than 100,000 ICDs are implanted in the United States (US) annually, [6] with the majority of these (about 75%) implanted for primary prevention. [6] The mean age of patients receiving new implants is $66 + 13$ years and 43% of the new implants occur in patients > 70 years of age; [6] however, patients > 70 years of age are underrepresented in the large clinical trials that have shown ICD benefit as a whole. A subgroup analysis of MADIT-II trial showed mortality benefit of ICD in patients > 70 years of age in multivariate analysis (HR 1.57, 1.02–2.41, $p = 0.042$). [7]

Key Words:

Implantable Cardioverter-Defibrillator, primary prevention, secondary prevention

Corresponding Author:

Rahul Jain MD, MPH
Assistant Professor of Medicine

Indiana University Ann Arbor, MI 48106.

However, other studies have not shown consistent mortality benefit in this population. [8],[9],[10] This is also true in patients receiving an ICD for secondary prevention. [11] With advancing age and comorbidity burden, the relative contribution of noncardiac or non-arrhythmic causes of death [12], [9] may increase compared to younger patients, potentially attenuating the benefits of ICD therapy in older patients. This might be true even for those who have ICD implanted for secondary prevention. The ratio of sudden death to all cause death has been shown to fall steadily from 0.51 before age 50, to 0.26 after age 80, [9] especially in patients with heart failure or following myocardial infarction. Thus, one would expect that elderly survivors of cardiac arrest may benefit less from the ICD than younger patients. This might be especially true in the veteran patient population, which has increased cardiovascular risk factors when compared to the general population.

Procedural outcomes reported in the ≥ 70 yr age group have also varied considerably with some studies showing increased risk of complications in the elderly [13] while others have contradictory findings. [14] Current guidelines do not address the criteria or prognosis of ICD implantation with advancing age. [8],[9],[10] Given the considerable variation in the reported data, and lack of specific guidelines for ICD implantation at an advanced age, we sought

Table 1: Baseline Characteristics of the Study Population

Parameters	Baseline Values (N= 216)
Age (years)	76 ± 4
Male	99%
Primary Prophylaxis Indication	75%
Secondary Prophylaxis Indication	25%
Diabetes	55%
Hypertension	96%
Coronary Artery Disease	86%
Atrial fibrillation	35%
Left ventricular Ejection Fraction at time of Implantation	28 ± 12 %
NYHA Class II	27.3%
NYHA Class III	39.3%
GFR at the time of implantation	59 ± 24 ml/min
Beta Blockers	78.2%
ACE-inhibitors/ARB	79.2%
Spironolactone	9.7%
Diuretics	61.5%
Aspirin	79.2%
Dual Antiplatelet Therapy	20%
Anticoagulation	29.1%

to look into the long-term survival and procedural outcomes after ICD implantation in the elderly (age > 70 years) veteran population.

Methods

Study Population

We retrospectively studied 4800 patients who were enrolled in the device clinic at the Richard L Roudebush, Veterans Affairs (VA) Medical Center, in Indianapolis, IN. Patients with pacemakers were excluded from the study, leaving 1660 patients who had an ICD, of which 268 had ICD implanted at or after the age of 70 years. Data was incomplete in 48 patients who were excluded from further analysis. Thus, a total of 220 patients were included in the study for analysis. Patients underwent ICD implantation between 1995 and 2014. During the analysis of primary versus secondary indication, four patients were further excluded because data for indication for implantation was missing. The computerized patient record system (CPRS) database was reviewed for comorbidities at the time of implantation. This also included reading through the scanned data in CPRS for outside medical records. Device recordings of patients who had ICD therapies were reviewed by an electrophysiologist at the time of clinic visit and then adjudicated by a second electrophysiologist (RJ) during the review of records for this study. To clarify disagreement in categorization of stored events those recordings were presented in the morning conference and the consensus agreements were used for analysis.

Data Collection

Comorbidities

Comorbidities from the CPRS database were recorded at the time of initial implantation (or within 6 months thereafter). Ejection fraction data was collected through echocardiographic, nuclear medicine, or cardiac catheterization reports within 6 months prior to the date of ICD implantation.

Outcomes

The primary outcomes were all-cause mortality and appropriate

ICD therapy (anti-tachycardia pacing {ATP} or shock). Secondary outcomes include inappropriate therapy (ATP or shock), and device-related complications at ≤ 30 days and > 30 days post-implant. Mortality data was collected through CPRS. The European community and the International standards organization have provided standard criteria for adverse events observed during trials with implantable medical devices, defining an adverse event as any undesirable clinical occurrence and taking into account the severity and relationship to the implanted device. [15] In our study, we excluded inappropriate therapies as device related complication (analyzed separately). Adverse events post device implantation included lead or device revisions, infections, hematoma, lead fracture, and device recalls. This was further subdivided into procedure related complications where device recalls were not included.

Statistical Analysis

Continuous variables were summarized by mean (standard deviation) or median (interquartile range) and compared using two-sample T test (if the normality assumption holds) or Wilcoxon rank-sum test (if the normality assumption did not hold). Normality of distribution was determined using the Kolmogorov-Smirnov goodness-of-fit test. Categorical data was summarized by frequency and percentage and analyzed using Fishers exact test. Distributions of time to death were estimated by Kaplan-Meier method and compared using log-rank test. Distributions of time to appropriate and inappropriate therapies are estimated and compared using the method of sub-distribution hazard [16]. Cox proportional hazard models (for mortality) and proportional sub-distribution hazard models [17] were used to account for baseline covariates. A risk score for total mortality was created using risk factors in the multivariate Cox model, where the score is the linear sum of the products of the risk factor values and corresponding regression coefficients. The score was then rescaled to have a range of 0-100, where a higher score indicates a higher risk of death.

Calculation of risk score

x is the covariate of patient and includes six variables (Age at implant, DM, Hyperlipidemia, Atrial Fibrillation, CAD, COPD). β is the coefficient vector of the cox model for mortality.

The linear predictor for each patients is defined as $lp = x\beta$

The constant c is defined as $C = \text{Max}_{lp} - \text{Min}_{lp} / 100$

Max_{lp} is the maximum value of linear predictor for all patients in the sample set, the Min_{lp} is the minimum value of linear predictor for all patients in the sample set.

The risk score is defined as $\text{Score} = x\beta - \text{Min}_{lp} / C$. Then we can get the increment of the risk score when 1 unit increasing on the respective risk factors.

All analyses were performed using R 3.0. A two-sided p-value less than 0.05 is considered statistically significant.

Results

A total of 220 patients were included in the study. Baseline characteristics of the study population are shown in Table 1. The mean age of the study population was 76 ± 4 years. Except for one patient all were males. 161 (75%) patients had ICD implanted for primary prevention and 55 (25%) patients for secondary prevention. Overall, 119 (55%) patients had diabetes, 209 (96%) patients had hypertension, 186 (86%) patients had coronary artery disease (CAD), 76 (35%) patients had atrial fibrillation. Mean left ventricular ejection fraction (LVEF) at the time of implantation was 28 + 12%. There were 59 (27.3%) patients who had NYHA Class II heart failure




Figure 1: Kaplan Meier Curves comparing incidence of overall mortality, appropriate therapies and inappropriate therapies in primary versus secondary indication for implantation.

(HF) and 85 (39.3%) patients had NYHA Class III HF. Mean GFR was 59 ± 24 ml/min. There were 169 (78.2%) patients taking beta-blockers, 79.2% (n= 171) on ACE-inhibitors or angiotensin receptor blockers (ARBs), 9.7% (n= 22) spironolactone, 61.5% (n= 133) diuretics, 79.2% (n= 171) aspirin, 20% (n=44) dual antiplatelet therapy and 29.1% (n=63) on anticoagulants (primarily warfarin 26.8% {n=63}). Mean follow up was 1686 ± 1244 days. 116 (53%) patients died during this period. At baseline, only atrialfibrillation was significantly different (higher in primary prevention group, 40.4% versus 20%) between the two groups. (Table 2)

Overall Data Analysis for Mortality

Out of 216 patients in the study, 114 (52%) patients died during the follow up duration. Out of 114, 35 (31%) received appropriate ICD therapy and 16 (14%) had inappropriate therapy. On univariate analysis, higher age at the time of implant (HR: 1.07, [CI: 1.03, 1.12], $p = 0.002$), DM (HR: 1.66, [CI: 1.14, 2.4], $p = 0.008$), hyperlipidemia (HR: 1.69, [CI: 1.07, 2.67], $p = 0.02$), atrial fibrillation (HR: 1.54, [CI: 1.05, 2.27], $p = 0.03$), CAD (HR : 2.39, [CI: 1.33, 4.28], $p = 0.003$) and COPD (HR: 1.94, [CI: 1.31, 2.87], $p = 0.001$) were significantly associated with overall mortality. Age at the time of implant (HR: 1.10, [CI: 1.05, 1.15], $p = < 0.00010$), DM (HR: 1.62, [CI: 1.10, 2.40], $p = 0.02$), CAD (HR: 2.27, [CI: 1.24, 4.17], $p = 0.008$) and COPD (HR: 2.40, [CI: 1.60, 3.61], $p = < 0.0001$) were significantly associated with mortality when applied to a model to develop predictors of mortality in our data.

Overall Data Analysis for Appropriate Therapy

Out of 216 patients, 60 (28%) received appropriate ICD therapies. On univariate analysis, indication for implantation (primary versus secondary) {HR: 0.41, (CI: 0.25, 0.68), $p = 0.0005$ }, and hypertension {HR: 0.37, (CI: 0.16, 0.83), $p = 0.016$ } were significantly associated with appropriate therapy. In a predictive model for appropriate

ICD therapy, secondary prevention indication for implantation {HR: 0.43, (CI: 0.26, 0.70), $p = 0.0009$ } and hypertension {HR: 0.37, (CI: 0.15, 0.95), $p = 0.039$ } were the only two variables that predicted appropriate therapy. Patients with a secondary prophylaxis indication had 67 times higher risk chance of receiving appropriate therapy as compared to a primary prevention implant.

Overall Data Analysis for Inappropriate Therapy

Of the patients 216 patients, 28 (13%) received inappropriate therapies. On univariate analysis, age at the time of implantation {HR: 0.87, (CI: 0.80, 0.95), $p = 0.003$ } and presence of atrial fibrillation {HR: 2.19, (CI: 1.05, 4.6), $p = 0.04$ } were significantly associated with inappropriate therapies. In a predictive model for inappropriate therapy, age at time of implantation {HR: 0.87, (CI: 0.79, 0.95), $p = 0.002$ } and atrial fibrillation {HR: 2.33, (CI: 1.11, 4.89), $p = 0.025$ } remained significant predictors of inappropriate therapies.




Figure 2: Kaplan Meier Curves comparing incidence of overall mortality, appropriate therapies and inappropriate therapies in patients with ischemic versus non ischemic cardiomyopathy.

Mortality in Primary Versus Secondary Prevention Group

There were a total of 114 (52%) deaths. Out of these, 78 (48%) had received ICD implantation for a secondary prevention indication, while 36 (66%) were primary prevention implants. In patients who had the ICD implanted for primary prevention of SCD, the 1 year mortality was 9% and 5 year mortality was 39%, not significantly different as compared to 9% and 40% in the secondary prevention group.

Appropriate ICD Therapy in Primary Versus Secondary Prevention Group

Of the 60 (27.8%) patients who received appropriate shocks, 33 (20.5%) were in patients who had secondary prophylaxis as the indication for implantation. In patients who had the ICD implanted for secondary prophylaxis, 17% received appropriate shocks in 1 year and 37% within 5 years compared to 7% and 22% respectively for patients who received the ICD for primary prophylaxis. In 55 patients who received ICD for secondary prophylaxis, 36 (65.5%) received an appropriate shock.

Table 2: Baseline Characteristics

Characteristics	No. of Participants (%)			
	Total (n = 216)	Primary (n =161)	Secondary (n=55)	P Value
Age, mean (SD), y	76.38 (4.27)	76.40 (4.23)	76.45 (4.50)	0.94
Ischemic				0.21
Yes	191 (88.0)	139 (86.3)	51 (92.7)	
No	26 (12.0)	22 (13.7)	4 (7.3)	
DM				
Yes	119 (54.3)	91 (56.9)	28 (50.9)	0.44
No	100 (45.7)	69 (43.1)	27 (40.1)	
Hypertension				
Yes	209 (95.0)	156 (96.9)	51 (92.7)	0.18
No	11 (5.0)	5 (3.1)	4 (7.3)	
Smoking status				
Current smoker	48 (21.9)	36 (22.5)	10 (18.2)	0.78
Former smoker	70 (32.0)	52 (32.5)	18 (32.7)	
No smoking	101 (46.1)	72 (45.0)	27 (49.1)	
History of Hyperlipidemia				
Yes	169 (77.2)	126 (78.7)	42 (76.4)	0.71
No	50 (22.8)	34 (21.3)	13 (23.6)	
GFR time, mean (SD), ml/min	59.8 (21.3)	59.7 (21.6)	60.3 (20.4)	0.88
Chronic Kidney Disease				0.8
Yes	91 (41.5)	67 (41.9)	24 (43.6)	
No	128 (58.5)	93 (58.1)	31 (56.4)	
Atrial Fibrillation				
Yes	76 (34.5)	65 (40.4)	11 (20.0)	0.0063
No	144 (65.5)	96 (59.6)	44 (80.0)	
Coronary artery disease				
Yes	186 (84.5)	138 (85.7)	47 (85.5)	0.96
No	34 (15.5)	23 (14.3)	8 (14.5)	
Chronic obstructive pulmonary disease				
Yes	62 (28.3)	43 (26.9)	18 (32.7)	0.41
No	157 (71.7)	117 (73.1)	37 (67.3)	
Transient ischemic attack/stroke				
Yes	18(8.2)	15 (9.4)	3 (5.5)	0.37
No	201 (91.8)	145(90.6)	52 (94.5)	

Inappropriate ICD Therapy in Primary Versus Secondary Prevention Group

Of the 28 patients who received inappropriate shocks, 20 (12.4%) were in patients who had primary prophylaxis as the indication for implantation and the remaining 8 (14.5%) in secondary prophylaxis patients. In patients who had the ICD implanted for secondary prophylaxis, 6% received inappropriate shocks in 1 year and 10% within 5 years compared to 7% and 15% respectively for patients who received ICD for primary prophylaxis.

Adverse events post device implantation

Twenty-three (10.4%) patients had device related complications. Out of these 23 patients, 13 died, 4 received appropriate therapy and 3 had inappropriate therapy. Two patients had both appropriate and inappropriate therapies. Six patients (23%) had complications on the day of implant, 23% had within 30 days (excluding those who had on the day of implant) and 48% had complications after 30 days of implant.

Excluding device or lead recalls, 17 had complications (7.7%). The complications included infection, hematoma, lead fracture, coronary sinus dissection, right ventricular perforation and lead revision.

New Risk Score for Overall Mortality

Based on the available data we looked at possible predictors of overall mortality in septuagenarians referred for ICD implantation. A risk score was developed based on the variables that were significant for mortality in multivariable analysis for mortality. The overall mortality based on the risk score is shown in figure 3. To better understand this we can use the following examples:

1. A 75 year old patient without any risk variables has a score of 6.2.
 2. A patient who is 78 years old with diabetes mellitus, no hyperlipidemia, no atrial fibrillation, no CAD and no COPD has a score of 26.
 3. A patient who is 79 years old with diabetes mellitus, hyperlipidemia, atrial fibrillation, CAD and COPD has a score of 89.
- The survival curves in figure 3 can then be used to predict 1 year and 5 year mortality in the above patients.

Discussions

Life expectancy in general population at the age of 70 years is 14.2 years in males and 16.4 years in females^[18]. 53% of our study population died during the follow up period of 4.6 years with 1-year and 5-year mortality being 19% and 71% respectively. This is consistent with other studies with 1-year and 5-year mortality rates of around 20-40 % and 75-80% respectively in patients with heart failure and

Table 3a: Survival Analysis for all cause mortality

Parameters	Hazard ratio	95% CI	p value
Primary or secondary	1.22	(0.81 , 1.84)	0.334
Age at implant	1.07	(1.03 , 1.12)	0.00234
Ischemic	1.13	(0.62 , 2.08)	0.675
DM	1.66	(1.14 , 2.42)	0.00818
Hypertension	2.60	(0.95 , 7.15)	0.063
Smoking Status	1.37	(0.88 , 2.14)	0.159
	1.25	(0.79 , 1.97)	0.343
Hyperlipidemia	1.69	(1.07 , 2.67)	0.0243
GFR time	0.99	(0.98 , 1.00)	0.203
Chronic Kidney Disease	1.43	(0.99 , 2.08)	0.057
Atrial Fibrillation	1.54	(1.05 , 2.27)	0.027
CAD	2.39	(1.33 , 4.28)	0.00339
COPD	1.94	(1.31 , 2.87)	0.000922
TIA	0.94	(0.48 , 1.87)	0.87
LVEF	1.00	(0.99 , 1.02)	0.591

DM: Diabetes Mellitus, GFR: Glomerular filtration rate, CAD: Coronary artery disease, COPD: Chronic obstructive pulmonary disease, TIA: Transient ischemic attack, LVEF: Left ventricular ejection fraction.

mean age of >70 years [19], [20]. However, it is significantly different from the 1-year and 5-year mortality in MADIT- 2 trial comparing patients with ICD and no-ICD (8% vs. 10% and 33% vs. 43%) with mean age of 64 years [21] and 5-year mortality in the Sudden Cardiac Death in Heart Failure Trial SCD-HeFT trial comparing patients with ICD and placebo (29% vs 36%) with mean age of 60 years [22].

Further, in a subgroup analysis of MADIT-2 trial evaluating 204 elderly patients (aged >75 years) with ischemic cardiomyopathy, there was a non-significant trend towards benefit with ICD therapy (HR: 0.56; 95% CI: 0.29-1.08; P= 0.08). Similarly, subgroup analysis in SCD-HeFT [22] and Comparison of Medical Therapy, pacing and Defibrillation in Heart Failure (COMPANION) studies [23] also showed little mortality benefit. This could be secondary to an increase in non-arrhythmic causes of death with increasing age, which is not prevented by an ICD. [12], [9]

In our study, age at the time of implant, DM, CAD, COPD and atrial fibrillation was predictors of all-cause mortality. This is similar to the report of Lee et al. [12] that showed age and noncardiac comorbidities influence survival in the care of ICD recipients. They used administrative data to show that survival after ICD implantation was inversely related to an increasing number

of comorbidities. Buxton et [24] also reported a risk stratification and found that NYHA class, conduction disturbance, history of heart failure, LVEF, atrial fibrillation, and age were predictors of mortality. We did not find a difference in mortality in primary versus secondary as indication for implantation. However, the above mentioned comorbidities were associated significantly with mortality. In our study, 16.6 % and 22% of patients who had ICD implanted for secondary prophylaxis received appropriate therapy by 1 and 2 years respectively. This is much lower than what has been previously reported in the Antiarrhythmics Versus Implantable Defibrillator (AVID) trial. In that trial, at least one episode of therapy, either ATP or shock, was delivered in 51% of patients at 1 year, censoring patients who had died. [3] In our study 28% received appropriate therapy and 37% died without receiving any appropriate therapy. Patients who had ICD implanted for secondary prophylaxis were 57 times more likely to receive appropriate therapy compared to when primary prophylaxis was the indication for implantation. For reasons difficult to explain,

Table 4a: Univariate analysis for Appropriate therapy

Parameters	Hazard ratio	95% CI	p value
Primary or secondary	0.41	(0.25 , 0.68)	0.00045
Age at implant	0.97	(0.91 , 1.04)	0.43
Ischemic	0.99	(0.46 , 2.16)	0.98
DM	1.03	(0.62 , 1.70)	0.91
Hypertension	0.37	(0.16 , 0.83)	0.016
Smoking Status	1.10	(0.61 , 1.97)	0.75
	1.18	(0.63 , 2.20)	0.6
Hyperlipidemia	1.06	(0.59 , 1.93)	0.84
GFR time	1.00	(0.98 , 1.01)	0.54
Chronic Disease	Kidney 1.44	(0.87 , 2.37)	0.15
Atrial Fibrillation	0.80	(0.46 , 1.41)	0.45
CAD	1.74	(0.82 , 3.71)	0.15
COPD	1.48	(0.88 , 2.50)	0.14
TIA	0.96	(0.38 , 2.41)	0.93
LVEF	1.00	(0.98 , 1.02)	0.85

DM: Diabetes Mellitus, GFR: Glomerular filtration rate, CAD: Coronary artery disease, COPD: Chronic obstructive pulmonary disease, TIA: Transient ischemic attack, LVEF: Left ventricular ejection fraction.

hypertension was one of the predictors for appropriate therapies.

The appropriate therapy rate of 6.5% for primary prophylaxis is similar to the rate reported in the literature [3], [2]. In our study, 7.62 % of patients received inappropriate therapy at 2 years, 11% at 45.5 months and 12.9% at 5 years of follow up respectively. This is less than what has been reported in MADIT-II [25] and SCD-HeFT trials [22]. In SCD-HeFT, [22] 17% of patients received inappropriate shocks over a median of 45.5 months of follow-up. Similarly in MADIT-II, 13% of

Table 4b: Multivariate Analysis for Appropriate Therapy

Parameters	Hazard ratio	95% CI	p value
Primary or secondary	0.43	(0.26 , 0.70)	0.00081
Hypertension	0.37	(0.15 , 0.95)	0.039

Table 3b: Multivariate Analysis for All cause mortality

Parameters	Hazard ratio	95% CI	p value
Age at implant	1.10	(1.05 , 1.15)	0.0000682
DM	1.62	(1.10 , 2.40)	0.01438
Hyperlipidemia	1.29	(0.80 , 2.08)	0.29114
Atrial Fibrillation	1.47	(0.99 , 2.17)	0.05559
CAD	2.26	(1.23 , 4.15)	0.00857
COPD	2.41	(1.60 , 3.61)	0.0000248




Figure 3a: Overall mortality for subjects with different risk scores

Table 3a.1: Multivariate Analysis for All cause mortality

	1 year Mortality rate and 95 % CI		5 year Mortality rate and 95 % CI	
Score=80	0.2122	(0.1026 , 0.3217)	0.7207	(0.5672 , 0.8742)
Score=60	0.1067	(0.0502 , 0.1631)	0.4530	(0.3230 , 0.5830)
Score=40	0.0505	(0.0210 , 0.0799)	0.2419	(0.1480 , 0.3357)
Score=20	0.0243	(0.0062 , 0.0424)	0.1234	(0.0501 , 0.1967)

patients had inappropriate shocks during 2 years of follow-up [25].

In these studies, the most common cause of inappropriate shocks in decreasing order of frequency were atrial fibrillation; supraventricular tachycardia; and oversensing caused by lead fracture, T wave oversensing, and electromagnetic interference. In our study, age at the time of implant and presence of atrial fibrillation (AF) were predictors for inappropriate therapies. This is easily understandable. The prevalence of atrial fibrillation increases with age [26] with 2.3% at age 40 years and 5.9% at age 65 years. Approximately 70% of individuals with AF are between 65 and 85 years of age [27]. The finding that atrial fibrillation was a primary

Figure 3b: Incremental risk score with different variables.

Variables	Incremental Risk Score
Age at implant	2.4 per one year increase
DM	12.6
Hyperlipidemia	6.7
Atrial Fibrillation	10.0
Coronary artery disease	21.2
COPD	22.8

Table 5a: Univariate analysis for Inappropriate therapy

Parameters	Hazard ratio	95% CI	p value
Primary or secondary	0.97	(0.44 , 2.15)	0.95
Age at implant	0.87	(0.80 , 0.95)	0.0029
Ischemic Cardiomyopathy	0.76	(0.26 , 2.26)	0.62
DM	1.63	(0.76 , 3.51)	0.21
Hypertension	2.60	(0.95 , 7.15)	0.063
Smoking Status	0.62	(0.24 , 1.58)	0.31
	1.00	(0.41 , 2.43)	1
H/o Hyperlipidemia	0.62	(0.28 , 1.37)	0.23
GFR	1.01	(0.99 , 1.03)	0.26
Chronic Kidney Disease	0.67	(0.30 , 1.47)	0.32
Atrial Fibrillation	2.19	(1.05 , 4.56)	0.037
CAD	1.63	(0.48 , 5.55)	0.44
COPD	1.26	(0.56 , 2.78)	0.57
TIA	1.23	(0.39 , 3.86)	0.72
LVEF	1.01	(0.97 , 1.01)	0.42

DM: Diabetes Mellitus, GFR: Glomerular filtration rate, CAD: Coronary artery disease, COPD: Chronic obstructive pulmonary disease, TIA: Transient ischemic attack, LVEF: Left ventricular ejection fraction.

reason for inappropriate therapy, combined with the increased prevalence of atrial fibrillation with age, likely explains why we found associations of age and atrial fibrillation with inappropriate therapy

Overall device related adverse events in our study population was 10.5% which is higher compared to NCDR registry data

Table 5b: Multivariate Analysis for Inappropriate Therapy

Parameters	95% CI	p value
Age at implant	(0.79 , 0.95)	0.0019
Atrial Fibrillation	(1.11 , 4.89)	0.025

with complication rate of 5.8% in 2006 to 4.8% in 2010 in patients >65 years of age [28]. However, NDCR doesn't include device recalls as complications. If device/lead recalls are excluded from adverse events in our study, the complication rate drops to 7.7%, which is still higher than 4.8% mentioned above. Possible reasons for this higher incidence of complications include: 1. Infection and hematoma could be secondary to a higher incidence of advanced comorbidities in this age group. 2. Immunosenescence has been used to describe loss of immune functions in elderly individuals (> 65 years old). Although the mechanisms leading to immunosenescence are not clear, it has been associated with increased susceptibility to disease, infections, and poor response to treatments and vaccination [29].

Limitations

There are several limitations of this study. First, it is a retrospective study with a relatively small sample size. A detailed review of the records was done which included review of outside records, which were scanned in the CPRS. However, there could have been some arrhythmia episodes (therapy), which might have been missed and not recorded in the system. The veteran population is special with a different set of comorbidities from the general population and therefore the results of this study might not be generalized

Table 6: Device Related Complications in the Study Population

Patient	Indication	Age at Implantation (years)	Implant to Death (years)	Age at Death (years)	Time to Appropriate Therapy (days)	Time to Appropriate Therapy (days)	+/- 1 day of implant	< 30 Post Implant Complication	> 30 Day Post Implant Complication	Complication
209	Primary	73.2	0.8	74				Yes		Hematoma
133	Secondary	72.7	2.3	75					Yes	Infection
258	Primary	83.9	3.1	87					Yes	Lead fracture leading to multiple shocks
241	Primary	70.9	5.1	76	791				Yes	Recall
254	Primary	72.3	5.7	78					Yes	Vegetation on lead
131	Primary	77.3	6.7	84		63		Yes		Hematoma
194	Primary	79.1	6.9	86	497	1654			Yes	Recall
267	Primary	72.2	7.8	80			53	Yes		LV lead dislodgement
182	Primary	74.6	8.4	83				Yes		Device recall
193	Secondary	75.6	8.4	84		1440			Yes	Lead Fracture
66	Secondary	78.3	8.7	87				Yes		Recall-component failure
273	Secondary	70.6	9.4	80	191	2870			Yes	Lead fracture
260	Secondary	76.8	14.2	91	4473		Yes			Lead revision
41	Primary	77.4	0.85				Yes			Hematoma
54	Secondary	76.6							Yes	Battery recall
55	Primary	86.4			669				Yes	Battery recall
65	Primary	73.1						Yes		ICD pocket infection
101	Primary	75.7							Yes	LV lead noise
102	Primary	81.1							Yes	Infection
105	Primary	77.6					Yes			CS Dissection
106	Secondary	72.4			2424				Yes	Lead fracture
122	Secondary	73.2					Yes			RV perforation
129	Primary	72.2						Yes		Hematoma
141	Primary	75.9			306				Yes	Battery Recall
160	Primary	80.3						Yes		Hematoma

to the overall population. We propose a newer scoring system to estimate overall mortality when the patient is first seen in the clinic for an ICD. This needs validation in prospective study.

However, this is an important step for future prospective studies, which might lead to a new section in ICD guidelines, addressing this specific age group

Conclusion

To our knowledge, our study represents the first attempt to look into the natural history of ICDs when implanted at ≥ 70 years of age in veterans. This is a very special population with multiple different comorbidities. The findings from this study suggest that ICD implantation in the elderly should be given individualized consideration. We believe that current criteria for ICD implantation cannot be fully applied to this age group and prospective studies are needed for better define this age group.

References

1. Epstein, A.E., et al., ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *J Am Coll Cardiol*, 2008. 51(21): p. e1-62.
2. Connolly, S.J., et al., Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation*, 2000. 101(11): p. 1297-302.
3. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. *N Engl J Med*, 1997. 337(22): p. 1576-83.
4. Kuck, K.H., et al., Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). *Circulation*, 2000. 102(7): p. 748-54.
5. Connolly, S.J., et al., Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. *Eur Heart J*, 2000. 21(24): p. 2071-8.
6. Kremers, M.S., et al., The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. *Heart Rhythm*, 2013. 10(4): p. e59-65.
7. Goldenberg, I., et al., Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. *J Am Coll Cardiol*, 2008. 51(3): p. 288-96.
8. Panotopoulos, P.T., et al., Efficacy of the implantable cardioverter-defibrillator in the elderly. *J Am Coll Cardiol*, 1997. 29(3): p. 556-60.
9. Krahn, A.D., et al., Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. *Am Heart J*, 2004. 147(5): p.

837-40.

10. Santangeli, P., et al., Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. *Ann Intern Med*, 2010. 153(9): p. 592-9.
11. Healey, J.S., et al., Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. *Eur Heart J*, 2007. 28(14): p. 1746-9.
12. Lee, D.S., et al., Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. *J Am Coll Cardiol*, 2007. 49(25): P.Swindle, J.P., et al., 2408-15. 13. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. *Arch Intern Med*, 2010. 170(7): p. 631-7.
14. Duray, G., et al., Efficacy and safety of ICD therapy in a population of elderly patients treated with optimal background medication. *J Interv Card Electrophysiol*, 2005. 14(3): p. 169-73.
15. Rosenqvist, M., et al., Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. *Circulation*, 1998. 98(7): p. 663-70.
16. Gray, R.J., A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. *The Annals of Statistics*, 1988. 16(3): p. 1141-1154.
17. Fine, J.P. and R.J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk. *Journal of the American Statistical Association*, 1999. 94(446): p. 496-509.
18. Miller, F.C.B.a.M.L., Life Tables for the United States Social Security Area 1900-2100.
19. MacIntyre, K., et al., Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. *Circulation*, 2000. 102(10): p. 1126-31.
20. Goldberg, R.J., et al., Long-term survival after heart failure: a contemporary population-based perspective. *Arch Intern Med*, 2007. 167(5): p. 490-6.
21. Goldenberg, I., et al., Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. *Circulation*, 2010. 122(13): p. 1265-71.
22. Bardy, G.H., et al., Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med*, 2005. 352(3): p. 225-37.
23. Bristow, M.R., A.M. Feldman, and L.A. Saxon, Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. *J Card Fail*, 2000. 6(3): p. 276-85.
24. Buxton, A.E., et al., Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. *J Am Coll Cardiol*, 2007. 50(12): p. 1150-7.
25. Moss, A.J., et al., Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*, 2002. 346(12): p. 877-83.
26. Kannel, W.B., et al., Epidemiologic features of chronic atrial fibrillation: the Framingham study. *N Engl J Med*, 1982. 306(17): p. 1018-22.
27. Kistler, P.M., et al., Electrophysiologic and electroanatomic changes in the human atrium associated with age. *J Am Coll Cardiol*, 2004. 44(1): p. 109-16.
28. Borne, R.T., et al., Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006-2010. Results from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. *Circulation*, 2014. 130(10): p. 845-53.
29. Pawelec, G., Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics. *EMBO Rep*, 2007. 8(3): p. 220-3.